About SAGE Therapeutics (NASDAQ:SAGE)
SAGE Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company's lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor. The Company's next-generation product candidates, SAGE-217 and SAGE-689, also target the GABAA receptor system. The Company is focused on developing drugs based on selective allosteric modulation of CNS synaptic and extrasynaptic receptors. The Company's chemistry platform is focused on the chemical scaffolds of endogenous or chemically modified synthetic neuroactive steroid compounds that are allosteric modulators of GABAA or N-Methyl-D-aspartic acid or N-Methyl-D-aspartate (NMDA) receptors.
Industry, Sector and Symbol
Trailing P/E Ratio-24.188202247191
Forward P/E Ratio-19.72
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Book Value$11.58 per share
Price / Book14.20
Return on Equity-86.14%
Return on Assets-75.79%
SAGE Therapeutics (NASDAQ:SAGE) Frequently Asked Questions
What is SAGE Therapeutics' stock symbol?
SAGE Therapeutics trades on the NASDAQ under the ticker symbol "SAGE."
How were SAGE Therapeutics' earnings last quarter?
SAGE Therapeutics Inc (NASDAQ:SAGE) released its earnings results on Thursday, February, 22nd. The biopharmaceutical company reported ($1.75) EPS for the quarter, topping analysts' consensus estimates of ($1.98) by $0.23. During the same quarter in the prior year, the company earned ($1.50) earnings per share. View SAGE Therapeutics' Earnings History.
Where is SAGE Therapeutics' stock going? Where will SAGE Therapeutics' stock price be in 2018?
15 brokers have issued 12 month price targets for SAGE Therapeutics' stock. Their predictions range from $86.00 to $280.00. On average, they expect SAGE Therapeutics' stock price to reach $176.47 in the next twelve months. View Analyst Ratings for SAGE Therapeutics.
Who are some of SAGE Therapeutics' key competitors?
Some companies that are related to SAGE Therapeutics include BioMarin Pharmaceutical (BMRN), Grifols SA, Barcelona (GRFS), Alnylam Pharmaceuticals (ALNY), Genmab As (GNMSF), IPSEN (IPSEY), H. Lundbeck A/S- (HLUYY), bluebird bio (BLUE), Alkermes (ALKS), Jazz Pharmaceuticals (JAZZ), Seattle Genetics (SGEN), Beigene (BGNE), Neurocrine Biosciences (NBIX), Exelixis (EXEL), Stada Arzneimittel (STDAF), Ionis Pharmaceuticals (IONS), EXACT Sciences (EXAS), Valeant Pharmaceuticals Intl (VRX) and BIO-TECHNE (TECH).
Who are SAGE Therapeutics' key executives?
SAGE Therapeutics' management team includes the folowing people:
- Kevin P. Starr, Independent Chairman of the Board (Age 54)
- Jeffrey M. Jonas M.D., President, Chief Executive Officer, Director (Age 64)
- Kimi E. Iguchi, Chief Financial Officer, Treasurer (Age 53)
- Anne Marie Cook, Senior Vice President, General Counsel (Age 54)
- Amy Schacterle Ph.D., Senior Vice President - Regulatory Affairs and Quality Assurance
- Christopher Silber, Senior Vice President - Clinical Development
- Albert J. Robichaud Ph.D., Chief Scientific Officer (Age 54)
- Frank Sanders, Vice President of Sales and Marketing
- Paul Hodgkins, Vice President - Health Economics and Outcomes Research and Value Demonstration
- Thomas D. Anderson, Chief Commercial Strategy Officer (Age 60)
Has SAGE Therapeutics been receiving favorable news coverage?
News headlines about SAGE stock have trended somewhat negative recently, according to Accern. The research group ranks the sentiment of media coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. SAGE Therapeutics earned a daily sentiment score of -0.07 on Accern's scale. They also gave news coverage about the biopharmaceutical company an impact score of 44.48 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.
Who are SAGE Therapeutics' major shareholders?
SAGE Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.20%), Bank of New York Mellon Corp (3.86%), OppenheimerFunds Inc. (3.52%), Palo Alto Investors LLC (1.78%), Jennison Associates LLC (1.65%) and Eagle Asset Management Inc. (1.47%). Company insiders that own SAGE Therapeutics stock include Albert Robichaud, Jeffrey M Jonas, Kevin P Starr, Kimi Iguchi, Stephen Kanes and Steven M Paul. View Institutional Ownership Trends for SAGE Therapeutics.
Which institutional investors are selling SAGE Therapeutics stock?
SAGE stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, OppenheimerFunds Inc., Deutsche Bank AG, Artal Group S.A., Wells Fargo & Company MN, Picton Mahoney Asset Management, Amundi Pioneer Asset Management Inc. and UBS Asset Management Americas Inc.. Company insiders that have sold SAGE Therapeutics company stock in the last year include Albert Robichaud, Jeffrey M Jonas, Stephen Kanes and Steven M Paul. View Insider Buying and Selling for SAGE Therapeutics.
Which institutional investors are buying SAGE Therapeutics stock?
SAGE stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Carillon Tower Advisers Inc., Farallon Capital Management LLC, Emerald Advisers Inc. PA, Geode Capital Management LLC, Element Capital Management LLC, Tekla Capital Management LLC and California Public Employees Retirement System. View Insider Buying and Selling for SAGE Therapeutics.
How do I buy shares of SAGE Therapeutics?
Shares of SAGE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is SAGE Therapeutics' stock price today?
One share of SAGE stock can currently be purchased for approximately $164.43.
How big of a company is SAGE Therapeutics?
SAGE Therapeutics has a market capitalization of $7.88 billion. The biopharmaceutical company earns $-270,120,000.00 in net income (profit) each year or ($7.12) on an earnings per share basis. SAGE Therapeutics employs 257 workers across the globe.
How can I contact SAGE Therapeutics?
SAGE Therapeutics' mailing address is 215 FIRST STREET, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-299-8380 or via email at [email protected]
MarketBeat Community Rating for SAGE Therapeutics (SAGE)MarketBeat's community ratings are surveys of what our community members think about SAGE Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
SAGE Therapeutics (NASDAQ:SAGE) Analysts' Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Buy||Buy||Buy||Buy|
|Consensus Rating Score: ||2.80||2.79||2.79||2.92|
|Ratings Breakdown: ||1 Sell Rating(s)|
1 Hold Rating(s)
13 Buy Rating(s)
0 Strong Buy Rating(s)
|1 Sell Rating(s)|
1 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
|1 Sell Rating(s)|
1 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
2 Hold Rating(s)
10 Buy Rating(s)
1 Strong Buy Rating(s)
|Consensus Price Target: ||$176.47||$171.21||$171.21||$86.77|
|Price Target Upside: ||7.32% upside||0.12% upside||2.32% upside||33.88% upside|
SAGE Therapeutics (NASDAQ:SAGE) Consensus Price Target History
SAGE Therapeutics (NASDAQ:SAGE) Analyst Ratings History
(Data available from 3/19/2016 forward)
SAGE Therapeutics (NASDAQ:SAGE) Earnings History and Estimates Chart
SAGE Therapeutics (NASDAQ SAGE) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
SAGE Therapeutics (NASDAQ:SAGE) Earnings Estimates
2018 EPS Consensus Estimate: ($7.59)
(Earnings estimates data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for SAGE Therapeutics (NASDAQ:SAGE)
No dividend announcements for this company have been tracked by MarketBeat.com
SAGE Therapeutics (NASDAQ SAGE) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 6.10%
Institutional Ownership Percentage: 96.29%
SAGE Therapeutics (NASDAQ SAGE) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|3/6/2018||Steven M Paul||Director||Sell||58,139||$172.00||$9,999,908.00||632,712|| |
|1/10/2018||Stephen Kanes||Insider||Sell||44,000||$177.18||$7,795,920.00||46,348|| |
|12/21/2017||Jeffrey M Jonas||CEO||Sell||210,247||$157.45||$33,103,390.15||211,473|| |
|12/14/2017||Albert Robichaud||Insider||Sell||60,000||$159.43||$9,565,800.00||152,759|| |
|1/13/2017||Kimi Iguchi||CFO||Sell||10,000||$53.92||$539,200.00|| |
|11/17/2016||Kimi Iguchi||CFO||Sell||4,000||$51.77||$207,080.00||75,739|| |
|11/11/2016||Kimi Iguchi||CFO||Sell||1,500||$50.59||$75,885.00||79,739|| |
|9/7/2016||Kimi Iguchi||CFO||Sell||2,500||$40.93||$102,325.00||81,239|| |
|7/12/2016||Albert Robichaud||Insider||Sell||22,000||$40.00||$880,000.00||140,222|| |
|7/12/2016||Kimi Iguchi||CFO||Sell||5,000||$49.55||$247,750.00||83,739|| |
|5/16/2016||Kevin P Starr||Director||Sell||850,000||$31.25||$26,562,500.00||65,227|| |
|4/19/2016||Stephen Kanes||Insider||Sell||21,000||$38.00||$798,000.00||25,948|| |
|1/25/2016||Albert Robichaud||Insider||Sell||20,000||$40.02||$800,400.00||162,222|| |
|9/28/2015||Stephen Kanes||insider||Sell||6,000||$46.42||$278,520.00||46,948|| |
|9/8/2015||Kimi Iguchi||CFO||Sell||3,000||$54.84||$164,520.00||84,563|| |
|9/1/2015||Steven M. Paul||Director||Sell||20,000||$52.41||$1,048,200.00||683,650|| |
|8/31/2015||Stephen Kanes||Insider||Sell||12,000||$53.12||$637,440.00||31,948|| |
|7/23/2015||Jeffrey M Jonas||Insider||Sell||3,000||$76.79||$230,370.00|| |
|7/6/2015||Kimi Iguchi||CFO||Sell||4,000||$68.00||$272,000.00|| |
|7/1/2015||Albert Robichaud||Insider||Sell||16,000||$72.13||$1,154,080.00|| |
|7/1/2015||Steven M Paul||Director||Sell||20,000||$69.40||$1,388,000.00|| |
|6/24/2015||Stephen Kanes||Insider||Sell||6,000||$74.06||$444,360.00|| |
|6/16/2015||Jeffrey M Jonas||Insider||Sell||198,600||$77.36||$15,363,696.00|| |
|6/8/2015||Thomas Anderson||Insider||Sell||5,500||$79.65||$438,075.00|| |
|6/1/2015||Albert Robichaud||Insider||Sell||16,000||$72.80||$1,164,800.00|| |
|6/1/2015||Steven M Paul||Director||Sell||20,000||$72.34||$1,446,800.00|| |
|2/25/2015||Stephen Kanes||Insider||Sell||6,000||$42.05||$252,300.00|| |
|1/26/2015||Stephen Kanes||Insider||Sell||6,000||$37.29||$223,740.00|| |
|7/23/2014||James M Frates||Director||Buy||5,000||$18.00||$90,000.00|| |
|7/23/2014||Stephen Kanes||Insider||Buy||3,000||$18.00||$54,000.00|| |
SAGE Therapeutics (NASDAQ SAGE) News Headlines
|Corbus Pharmaceuticals (CRBP) vs. SAGE Therapeutics (SAGE) Head-To-Head Contrast|
www.americanbankingnews.com - March 18 at 5:20 PM
|Pre-Market Technical Scan on Biotech Equities -- Riot Blockchain, Sage ...|
www.prnewswire.com - March 16 at 8:58 AM
|Pre-Market Technical Scan on Biotech Equities -- Riot Blockchain, Sage Therapeutics, Sarepta Therapeutics, and Sierra Oncology|
www.bizjournals.com - March 16 at 8:58 AM
|See what the IHS Markit Score report has to say about SAGE Therapeutics Inc.|
finance.yahoo.com - March 15 at 5:35 PM
|Analyst Has 4 Favorite Biotechnology Stocks to Buy Now|
www.msn.com - March 15 at 5:35 PM
|SAGE Therapeutics (SAGE) Lifted to "Hold" at BidaskClub|
www.americanbankingnews.com - March 11 at 3:52 PM
|SAGE Therapeutics Inc (SAGE) Receives Average Recommendation of "Buy" from Analysts|
www.americanbankingnews.com - March 10 at 3:54 AM
|Insider Selling: SAGE Therapeutics Inc (SAGE) Director Sells 58,139 Shares of Stock|
www.americanbankingnews.com - March 8 at 6:12 PM
|Here's Why Marinus Pharmaceuticals Dropped as Much as 17.7% Today|
finance.yahoo.com - March 6 at 5:17 PM
|Biotech Jumps After Rival Pushes Back Depression Drug Tests|
finance.yahoo.com - March 6 at 5:17 PM
|17,200 Shares in SAGE Therapeutics Inc (SAGE) Acquired by Sectoral Asset Management Inc|
www.americanbankingnews.com - March 6 at 2:11 PM
|American International Group Inc. Acquires 2,309 Shares of SAGE Therapeutics Inc (SAGE)|
www.americanbankingnews.com - March 6 at 4:22 AM
|SAGE Therapeutics Inc (SAGE) Stake Lessened by UBS Asset Management Americas Inc.|
www.americanbankingnews.com - March 2 at 7:50 PM
|SAGE Therapeutics Inc (SAGE) Shares Bought by State of Wisconsin Investment Board|
www.americanbankingnews.com - March 1 at 6:10 PM
|Analysts Offer Predictions for SAGE Therapeutics Inc's Q1 2018 Earnings (SAGE)|
www.americanbankingnews.com - March 1 at 7:14 AM
|Analysts Issue Forecasts for SAGE Therapeutics Inc's FY2022 Earnings (SAGE)|
www.americanbankingnews.com - February 28 at 4:48 PM
|SAGE Therapeutics (SAGE) PT Raised to $203.00|
www.americanbankingnews.com - February 28 at 4:44 PM
|EAM Investors LLC Invests $3.28 Million in SAGE Therapeutics Inc (SAGE) Stock|
www.americanbankingnews.com - February 28 at 1:56 PM
|SAGE Therapeutics Inc (SAGE) Position Increased by BlackRock Inc.|
www.americanbankingnews.com - February 28 at 5:16 AM
|SAGE Therapeutics Inc (SAGE) Shares Bought by California Public Employees Retirement System|
www.americanbankingnews.com - February 27 at 5:20 AM
|Morgan Stanley Gets Wise On Sage Therapeutics, Initiates With A Buy|
finance.yahoo.com - February 26 at 5:22 PM
|SAGE Therapeutics (SAGE) Research Coverage Started at Morgan Stanley|
www.americanbankingnews.com - February 26 at 2:35 PM
|SAGE Therapeutics Inc Forecasted to Earn Q3 2018 Earnings of ($1.92) Per Share (SAGE)|
www.americanbankingnews.com - February 26 at 4:37 AM
|Analyzing Oncobiologics (ONS) and SAGE Therapeutics (SAGE)|
www.americanbankingnews.com - February 25 at 9:24 AM
|Carillon Tower Advisers Inc. Acquires Shares of 451,097 SAGE Therapeutics Inc (SAGE)|
www.americanbankingnews.com - February 25 at 4:58 AM
|Sage Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results and Provides Pipeline Update - Business Wire (press release)|
www.businesswire.com - February 24 at 8:44 AM
|SAGE Therapeutics' (SAGE) Buy Rating Reaffirmed at Needham & Company LLC|
www.americanbankingnews.com - February 23 at 5:51 PM
|Zacks: Brokerages Anticipate SAGE Therapeutics Inc (SAGE) Will Announce Earnings of -$2.04 Per Share|
www.americanbankingnews.com - February 22 at 5:20 PM
|Cellular Dynamics International (ICEL) & SAGE Therapeutics (SAGE) Financial Survey|
www.americanbankingnews.com - February 22 at 1:18 PM
|SAGE Therapeutics (SAGE) Issues Quarterly Earnings Results|
www.americanbankingnews.com - February 22 at 12:32 PM
|Form 10-K Sage Therapeutics, Inc. For: Dec 31|
www.streetinsider.com - February 22 at 8:48 AM
|Sage Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results and Provides Pipeline Update|
finance.yahoo.com - February 22 at 8:48 AM
|SAGE Therapeutics (SAGE) Cut to Sell at BidaskClub|
www.americanbankingnews.com - February 19 at 1:24 PM
|Sage Therapeutics to Report Fourth Quarter and Full Year 2017 Financial Results on Thursday, February 22, 2018|
finance.yahoo.com - February 13 at 9:40 AM
|SAGE Therapeutics Inc (SAGE) Receives Consensus Recommendation of "Buy" from Brokerages|
www.americanbankingnews.com - February 13 at 3:30 AM
|Sage Therapeutics to Present at Leerink Partners 7th Annual Global Healthcare Conference|
finance.yahoo.com - February 12 at 4:05 PM
|Today’s Research Reports on Stocks to Watch: Sarepta Therapeutics and Sage Therapeutics|
finance.yahoo.com - February 12 at 9:33 AM
|Gilead Sciences And Sage Therapeutics Just Picked Up Big FDA Decisions|
finance.yahoo.com - February 8 at 4:01 PM
|Sage Therapeutics Receives FDA Breakthrough Therapy Designation for SAGE-217 for the Treatment of Major Depressive Disorder|
finance.yahoo.com - February 7 at 9:40 AM
|SAGE Therapeutics (SAGE) Lifted to Hold at BidaskClub|
www.americanbankingnews.com - February 3 at 9:12 AM
|Sage Therapeutics Wants to Show Its Treatment Can Help People Sleep|
finance.yahoo.com - February 2 at 9:35 AM
|Blog Exposure - Sage Therapeutics Declared Positive Results from Phase-1/2 Clinical Trial of SAGE-217 in Treatment of Insomnia|
finance.yahoo.com - February 2 at 9:35 AM
|Sage Therapeutics Just Popped To A Record High — Here's Why|
finance.yahoo.com - February 1 at 4:01 PM
|Commit To Buy Sage Therapeutics At $130, Earn 13.4% Using Options|
www.nasdaq.com - January 31 at 4:04 PM
|Sage Therapeutics Announces Positive Results from Placebo-Controlled Trial in a Model of Insomnia Demonstrating Activity on Sleep Parameters and Supporting Development of SAGE-217 as Potential Treatment for Sleep Disorders|
finance.yahoo.com - January 31 at 9:59 AM
|SAGE Therapeutics Inc (SAGE) Given Average Recommendation of "Buy" by Analysts|
www.americanbankingnews.com - January 19 at 4:34 AM
|SAGE Therapeutics (SAGE) vs. aTyr Pharma (LIFE) Financial Survey|
www.americanbankingnews.com - January 16 at 1:10 AM
|Stephen Kanes Sells 44,000 Shares of SAGE Therapeutics Inc (SAGE) Stock|
www.americanbankingnews.com - January 12 at 6:26 PM
|Bloomberg Markets: Sage Battling Depression, Powerful Culture|
www.bloomberg.com - January 11 at 12:03 PM
|SAGE Therapeutics (SAGE) Given "Buy" Rating at JPMorgan Chase & Co.|
www.americanbankingnews.com - January 10 at 8:20 AM
SAGE Therapeutics (NASDAQ:SAGE) SEC Filings
This page is loading this company's SEC Filings. Please wait...
SAGE Therapeutics (NASDAQ:SAGE) Income Statement, Balance Sheet and Cash Flow Statement
SAGE Therapeutics (NASDAQ SAGE) Stock Chart for Monday, March, 19, 2018